These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 30130546)

  • 1. Serum Testosterone Levels and Prostate Cancer Risk: A Single Post-Hoc Testosterone Measurement is Not Informative.
    Loughlin KR
    J Urol; 2019 Jan; 201(1):40-41. PubMed ID: 30130546
    [No Abstract]   [Full Text] [Related]  

  • 2. New concepts regarding the relationship of testosterone and prostate cancer.
    Morgentaler A
    Future Oncol; 2007 Apr; 3(2):123-6. PubMed ID: 17381410
    [No Abstract]   [Full Text] [Related]  

  • 3. Testosterone and prostate cancer.
    Tubaro A
    Eur Urol; 2007 Feb; 51(2):293-5. PubMed ID: 17034931
    [No Abstract]   [Full Text] [Related]  

  • 4. The testosterone conundrum: The putative relationship between testosterone levels and prostate cancer.
    Loughlin KR
    Urol Oncol; 2016 Nov; 34(11):482.e1-482.e4. PubMed ID: 27423822
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum Testosterone Levels in Early Prediction of Prostate Cancer Risk.
    Bentmar Holgersson M; Malm J; Lundberg Giwercman Y
    Eur Urol; 2017 Jun; 71(6):992-994. PubMed ID: 27993425
    [No Abstract]   [Full Text] [Related]  

  • 6. Association between serum sex hormone levels and prostate cancer: effect of prostate cancer on serum testosterone levels.
    Imamoto T; Suzuki H; Utsumi T; Endo T; Takano M; Yano M; Kawamura K; Kamiya N; Nihei N; Naya Y; Ichikawa T
    Future Oncol; 2009 Sep; 5(7):1005-13. PubMed ID: 19792969
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Roux-en-Y gastric bypass on testosterone and prostate-specific antigen.
    Woodard G; Ahmed S; Podelski V; Hernandez-Boussard T; Presti J; Morton JM
    Br J Surg; 2012 May; 99(5):693-8. PubMed ID: 22302466
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The relationship between total testosterone levels and prostate cancer: a review of the continuing controversy.
    Klap J; Schmid M; Loughlin KR
    J Urol; 2015 Feb; 193(2):403-13. PubMed ID: 25260832
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Relationship between serum testosterone levels and prostatic cancer].
    Rivera P; Tagle R; Mir S; González R
    Actas Urol Esp; 2003; 27(10):788-92. PubMed ID: 14735860
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High serum dihydrotestosterone examined by ultrasensitive LC-MS/MS as a predictor of benign prostatic hyperplasia or Gleason score 6 cancer in men with prostate-specific antigen levels of 3-10 ng/mL.
    Miyoshi Y; Uemura H; Suzuki K; Shibata Y; Honma S; Harada M; Kubota Y
    Andrology; 2017 Mar; 5(2):262-267. PubMed ID: 27813361
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hormonal predictors of prostate cancer.
    Sofikerim M; Eskicorapci S; Oruç O; Ozen H
    Urol Int; 2007; 79(1):13-8. PubMed ID: 17627161
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The relationship between total and free serum testosterone and the risk of prostate cancer and tumour aggressiveness.
    Morote J; Ramirez C; Gómez E; Planas J; Raventós CX; de Torres IM; Catalán R
    BJU Int; 2009 Aug; 104(4):486-9. PubMed ID: 19220251
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serological precursors of cancer: serum hormones and risk of subsequent prostate cancer.
    Hsing AW; Comstock GW
    Cancer Epidemiol Biomarkers Prev; 1993; 2(1):27-32. PubMed ID: 8420607
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum inhibin--not a cause of low testosterone levels in hypogonadal prostate cancer?
    Lackner JE; Maerk I; Koller A; Bieglmayer C; Marberger M; Kratzik C; Schatzl G
    Urology; 2008 Nov; 72(5):1121-4. PubMed ID: 18407338
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The clinical potential of pretreatment serum testosterone level to improve the efficiency of prostate cancer screening.
    Yano M; Imamoto T; Suzuki H; Fukasawa S; Kojima S; Komiya A; Naya Y; Ichikawa T
    Eur Urol; 2007 Feb; 51(2):375-80. PubMed ID: 17005316
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potentially harmful effect of a testosterone dietary supplement on prostate cancer growth and metastasis.
    Shariat SF; Lamb DJ; Roehrborn CG; Slawin KM
    Arch Intern Med; 2008 Jan; 168(2):235-6. PubMed ID: 18227373
    [No Abstract]   [Full Text] [Related]  

  • 17. Getting over testosterone: postulating a fresh start for etiologic studies of prostate cancer.
    Carpenter WR; Robinson WR; Godley PA
    J Natl Cancer Inst; 2008 Feb; 100(3):158-9. PubMed ID: 18230791
    [No Abstract]   [Full Text] [Related]  

  • 18. Testosterone measurement in patients with prostate cancer.
    Schulman CC; Irani J; Morote J; Schalken JA; Montorsi F; Chlosta PL; Heidenreich A
    Eur Urol; 2010 Jul; 58(1):65-74. PubMed ID: 20434831
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Testosterone levels in benign prostatic hypertrophy and prostate cancer.
    Mearini L; Costantini E; Zucchi A; Mearini E; Bini V; Cottini E; Porena M
    Urol Int; 2008; 80(2):134-40. PubMed ID: 18362481
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The prognostic impact of serum testosterone during androgen-deprivation therapy in patients with metastatic prostate cancer and the SRD5A2 polymorphism.
    Shiota M; Fujimoto N; Yokomizo A; Takeuchi A; Kashiwagi E; Dejima T; Kiyoshima K; Inokuchi J; Tatsugami K; Eto M
    Prostate Cancer Prostatic Dis; 2016 Jun; 19(2):191-6. PubMed ID: 26857022
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.